Rani Therapeutics Holdings (RANI) Shares Outstanding (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Shares Outstanding (Entity) of $180.0 million for Q1 2026, up 436.18% year-over-year from $33.6 million in Q1 2025, and up 272052.17% quarter-over-quarter from $66138.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Shares Outstanding (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $180.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 436.18% year-over-year to $180.0 million; the TTM figure through Mar 2026 stood at $180.0 million (up 436.18% YoY), while the FY2025 annual figure was $66138.0, up 132.26% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $180.0 million, up from $66138.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $180.0 million in Q1 2026, with the low at $23817.0 in Q4 2022.
- The 5-year median for Shares Outstanding (Entity) is $25.5 million (2023), against an average of $31.2 million.
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Entity) plunged 99.88% in 2022, then soared 436.18% in 2026.
- Rani Therapeutics Holdings' Shares Outstanding (Entity) stood at $23817.0 in 2022, then rose by 7.09% to $25505.0 in 2023, then rose by 11.65% to $28476.0 in 2024, then jumped by 132.26% to $66138.0 in 2025, then jumped by 272052.17% to $180.0 million in 2026.
- Business Quant data shows RANI's Shares Outstanding (Entity) at $180.0 million in Q1 2026, $66138.0 in Q4 2025, and $47.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | 187.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187.17 Mn |
| Mar 31, 2026 | 180.00 Mn |
| Dec 31, 2025 | 66,138.00 |
| Sep 30, 2025 | 46.44 Mn |
| Jun 30, 2025 | 36.54 Mn |
| Mar 31, 2025 | 33.44 Mn |
| Dec 31, 2024 | 28,476.00 |
| Sep 30, 2024 | 28.84 Mn |
| Jun 30, 2024 | 26.32 Mn |
| Mar 31, 2024 | 26.03 Mn |
| Dec 31, 2023 | 25,505.00 |
| Sep 30, 2023 | 25.55 Mn |
| Jun 30, 2023 | 25.35 Mn |
| Mar 31, 2023 | 25.24 Mn |
| Dec 31, 2022 | 23,817.00 |
| Sep 30, 2022 | 24.47 Mn |
| Jun 30, 2022 | 24.37 Mn |
| Mar 31, 2022 | 21.41 Mn |
| Dec 31, 2021 | 19.53 Mn |
| Sep 30, 2021 | 19.44 Mn |